Weekly paclitaxel (PAC), pegylated liposomal doxorubicin (PLD) or topotecan (TOP) ± bevacizumab (BEV) in platinum (PT)-resistant recurrent ovarian cancer (OC): Analysis by chemotherapy (CT) cohort in the GCIG AURELIA randomised phase III trial

A. Poveda